iRadimed (NASDAQ:IRMD – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.
Profitability
This table compares iRadimed and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iRadimed | 27.36% | 24.48% | 21.25% |
| Beta Bionics | -60.27% | -23.00% | -20.55% |
Institutional & Insider Ownership
92.3% of iRadimed shares are held by institutional investors. 36.8% of iRadimed shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iRadimed | $83.81 million | 14.24 | $22.48 million | $1.83 | 51.01 |
| Beta Bionics | $100.25 million | 5.20 | -$73.20 million | ($1.51) | -7.75 |
iRadimed has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
iRadimed has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.29, meaning that its stock price is 229% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for iRadimed and Beta Bionics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iRadimed | 0 | 1 | 3 | 1 | 3.00 |
| Beta Bionics | 1 | 3 | 7 | 1 | 2.67 |
iRadimed presently has a consensus price target of $120.00, suggesting a potential upside of 28.54%. Beta Bionics has a consensus price target of $20.00, suggesting a potential upside of 70.79%. Given Beta Bionics’ higher possible upside, analysts plainly believe Beta Bionics is more favorable than iRadimed.
Summary
iRadimed beats Beta Bionics on 10 of the 14 factors compared between the two stocks.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
